SuperSonic Imagine

SuperSonic Imagine’s ultrasound platforms—especially the Aixplorer and MACH series—are clinically validated for high-resolution, real-time elastography and advanced Doppler imaging. Their ShearWave Elastography is supported by over 600 published articles demonstrating diagnostic value in breast, liver, prostate, and other soft tissue diseases[4][6]. SuperSonic Imagine is a French medical device company specializing in innovative ultrasound solutions featuring UltraFast® technology and real-time ShearWave Elastography—a breakthrough that enables non-invasive assessment of tissue stiffness for improved diagnosis of breast cancer and other diseases. Founded in 2005 through academic-industry collaboration with ESPCI Paris/CNRS labs,[5] the company has become a global leader with over two thousand installations worldwide.[4] Its flagship products include the Aixplorer series and MACH platforms,[1][7] which are widely used across oncology diagnostics (breast/liver/prostate), hepatology/fibrosis staging,[6] musculoskeletal medicine,[10], vascular applications,[10], OB-GYN/pediatrics.[8] In late 2019 it was acquired by Hologic to complement its women’s health portfolio.[8] The company remains active as an innovator within Hologic’s broader diagnostic business. No drug development pipeline exists—their focus is entirely on medical devices/imaging platforms rather than therapeutics or molecular targets. Their technologies have set new standards of care especially for non-invasive characterization of soft tissue diseases using elastography modalities validated by hundreds of clinical studies.[1][6] Main headquarters remain in Aix-en-Provence, France. Employee count estimated at between fifty to two hundred staff members globally.[4] Key technological differentiators include UltraFast acquisition speeds (>20k frames/sec), ergonomic design features like SonicPad™, automated protocols/workflow tools,[1], broad multi-specialty application support including CE/FDA clearances.[4] Their main customer base includes hospitals/radiology centers worldwide rather than pharmaceutical partners or licensees. No public trading symbol post-acquisition by Hologic.